A. Elezoglou, N. Kafasi, P.H. Kaklamanis, P.G. Theodossiadis, V. Kapsimali, E. Choremi, G. Vaiopoulos, P.P. Sfikakis
Dept. of Internal Medicine, Laikon Hospital, Athens University Medical School, Athens, Greece.
2007 Vol.25, N°4 ,Suppl.45 - PI 0065, PF 0069
To study autoantibody formation in patients with Behçet’s disease (BD) who received long-term treatment with the anti-TNF monoclonal antibody infliximab.
Serial sera from infliximab-treated patients (5 mg/kgr at weeks 0, 4, 8, and every 6-8 weeks thereafter) were tested for various autoantibodies, using commercially available methods, at baseline and at 6 months (n = 20), at 12 months (n = 16), and at 18 months post-baseline (n = 12). Thirty-five age- and sex-matched BD patients, not treated with infliximab, served as controls.
Autoantibodies were rarely seen in controls, as well as in infliximab treated patients at baseline. Formation of antinuclear antibodies (ANA) at low titers was evident in 13/20 (65%) patients at 6 months post-baseline; one additional patient developed anti-beta2 glycoprotein-I IgM antibodies (anti-Β
Early induction of ANA and specific autoantibodies is common in BD patients treated with infliximab, including low titers of non-pathogenic anti-dsDNA and anti-Β
PMID: 17949554 [PubMed]